Latest White Paper
- |
- 2025
- |
- 2025-06-16
New Product Alert – Ruxolitinib Phosphate
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.This inhibition disrupts cytokine and growth factor signalling pathw... [更多 ]
Year 2025
- |
- 2025
- |
- 2025-06-16
New Product Alert – Ruxolitinib Phosphate
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.This inhibition disrupts cytokine and growth factor signalling pathw... [更多 ]
- |
- 2025
- |
- 2025-05-26
Product Alert - Rimegepant
Rimegepant is a calcitonin gene-related peptide receptor antagonistOur Offerings*:Offers Crystalline Form (Innovator form 1.5 Hydrate)Alternate salt will provide 2 Years & 4 months advantage in Brazil & RussiaPlanning adequate capacity with a short lead time of 90 days.Lab samples and ATR av... [更多 ]
- |
- 2025
- |
- 2025-05-05
Product Alert – Mavacamten
CAS No. 1642288-47-8Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridg... [更多 ]
- |
- 2025
- |
- 2025-04-24
New Product Alert - Ripretinib
Ripretinib works by binding to two key regions of the kinase (the switch pocket and activation loop), locking it in an inactive state. This prevents the kinase from promoting abnormal cell growth, effectively inhibiting a wide range of mutations in KIT and PDGFRA kinases.Our Offerings*:Offers stable... [更多 ]
- |
- 2025
- |
- 2025-03-04
Product Alert - Lumateperone Tosylate
Lumateperone is a serotonin 5HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM), and a serotonin transporter (SERT) inhibitor. Unlike existing schizophrenia treatments, Lumateperone is a first-in-class molecule that provides selective and simultaneous modulation of seroton... [更多 ]
- |
- 2025
- |
- 2025-02-12
New Product Alert - Ribociclib
is a cancer medication that works by inhibiting the activity of specific enzymes called cyclin-dependent kinases (CDKs) 4 and 6. These enzymes play a critical role in the regulation of cell division, and their overactivity is commonly associated with the development of certain types of cancer, parti... [更多 ]
- |
- 2025
- |
- 2025-01-10
New Product Alert - Ruxolitinib & Salts
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.This inhibition disrupts cytokine and growth factor signalling pathw... [更多 ]
Year 2024
- |
- 2024
- |
- 2024-12-18
Tech Sheet On Nilotinib Hydrochloride
Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, Nilotinib inhibited BCR-ABL-mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ chronic mye... [更多 ]
- |
- 2024
- |
- 2024-10-18
Tech Sheet – Mirabegron API
CAS no. 223673-61-8Mirabegron is a ß-3 adrenergic receptor agonist and a widely prescribed oral drug for treating overactive bladder (OAB). The drug improves symptoms associated with OAB, such as urinary urgency or urgency incontinence.Mirabegron was approved under the trade names Myrbetriq (US, 201... [更多 ]
- |
- 2024
- |
- 2024-09-25
Tech sheet – Apremilast
Dr. Reddy's API Offerings*:Dr. Reddy's is among the earliest generic API manufacturers globally for Apremilast API and filed the USDMF in September 2016 (Form-B) and June 2017 (Amorphous). Besides this, we have DMF filings in Canada and Brazil.Offers the same form as the innovator drug, facilitating... [更多 ]
- |
- 2024
- |
- 2024-05-31
Product Alert - Relugolix API
CAS No: 737789-87-6As an early mover in API development, we are committed to regulatory compliance, have DMFs filling in the US and Brazil, and plan to file the DMFs in significant markets. Our API is available in an anhydrous crystalline form (the innovator form), which can be provided in customize... [更多 ]
- |
- 2024
- |
- 2024-05-31
Tech Sheet on Enzalutamide Premix
Chemical Name:4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N- methylbenzamide.Dr. Reddy's API Offerings*:Innovator has filed an Enzalutamide premix amorphous form manufactured through spray drying, which uses API and HPMCAS as excipients. We offer a... [更多 ]
- |
- 2024
- |
- 2024-05-31
Product Alert – Mirogabalin Besylate
Dr. Reddy's Offerings*:Planning USDMF by January 2025Offers crystalline Form-1Non-GMP API and COA are available.Quality Assurance through cGMP API ManufacturingManufacturing facilities have successfully undergone inspections by international regulatory authorities.Partnerships with reliable key star... [更多 ]
- |
- 2024
- |
- 2024-04-22
Product Alert – Vonoprazan Fumarate
Dr. Reddy's Offerings:USDMF filed in februray 2024Offers crystalline innovator form.Our API adheres to ICH M7 guidelines for genotoxic impurity (GTI) profiles, and we are actively evaluating strategies for nitrosamine impurities. We have also employed a robust process to achieve the consistent polym... [更多 ]
- |
- 2024
- |
- 2024-02-21
Tech Sheet - Cabozantinib (S)-malate API
Cabozantinib S-malate is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.Dr. Reddy's API Offering*We offer Cabozantinib S-malate – Crystalline form N2 (Innovator form).Cabozantinib HCl is an alternate salt providing 505(b)(2) opp... [更多 ]
Year 2023
- |
- 2023
- |
- 2023-12-07
Product Alert – Deucravacitinib API
CAS no. 1609392-27-9Dr. Reddy's API OfferingWe are targeting crystalline Form and working on other amorphous solid dispersions (ASDs) as well. Our API adheres to ICH M7 guidelines for genotoxic impurity (GTI) profiles, and we are actively evaluating strategies for nitrosamine impurities. We have als... [更多 ]
- |
- 2023
- |
- 2023-12-04
Substantially Pure Carfilzomib Amorphous for Generic Launch
Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic... [更多 ]
- |
- 2023
- |
- 2023-11-06
Product Alert – Mavacamten API
CAS no. 1642288-47-8Mavacamten (Camzyos®) is the pioneering and singularly authorised cardiac myosin inhibitor designed to address hypertrophic cardiomyopathy (HCM) at its root cause. This unique compound acts as an allosteric and reversible inhibitor with a specific focus on cardiac myosin, allowin... [更多 ]
- |
- 2023
- |
- 2023-07-21
White Paper on Sugammadex API
Sugammadex is a medication used to reverse the effects of certain muscle-relaxing drugs (rocuronium and vecuronium) during anaesthesia. It works by forming a complex with these drugs, neutralizing their effects, and restoring muscle function, allowing for a rapid reversal of muscle relaxation. Sugam... [更多 ]
- |
- 2023
- |
- 2023-07-21
Tech Sheet on Pregabalin API
Pregabalin's precise mechanism of action is not fully understood, but studies suggest that it binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding modulates the release of excitatory neurotransmitters and prevents the trafficking of the alph... [更多 ]
- |
- 2023
- |
- 2023-03-20
Product Alert – Niraparib API
Niraparib binds to the PARP enzyme and prevents it from repairing single-strand breaks in DNA. This causes the cancer cell's DNA to become more damaged, leading to cell death. Since cancer cells often have more DNA damage than healthy cells, they are more sensitive to the effects of PARP inhibitors ... [更多 ]
- |
- 2023
- |
- 2023-03-13
Product Alert – Tucatinib API
Tucatinib is a small molecule tyrosine kinase inhibitor that selectively targets human epidermal growth factor receptor 2 (HER2). HER2 is a transmembrane receptor that is overexpressed in some types of cancer, including breast cancer.Tucatinib binds to the intracellular domain of HER2, which blocks ... [更多 ]
- |
- 2023
- |
- 2023-03-06
Product Alert – Pazopanib API
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kin... [更多 ]
- |
- 2023
- |
- 2023-01-20
Tech Sheet on Midostaurin API
Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that Midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type ... [更多 ]
- |
- 2023
- |
- 2023-01-09
Tech Sheet on Tofacitinib Citrate
Tofacitinib Citrate (Xeljanz) is an oral, small molecule drug used to treat adults with moderate to severe active rheumatoid arthritis (RA), active psoriatic arthritis, and moderate to severe ulcerative colitis. Tofacitinib works by blocking the body’s production of enzymes called Janus kinases (JAK... [更多 ]
Year 2022
- |
- 2022
- |
- 2024-08-04
Addressing the presence of mutagenic Azido impurities in Sartan APIs
In continuation to our efforts to understand the Azido impurities, we are evaluating the possibility of formation of two additional Azido impurities - Chloro methyl azido impurity and 4-Chloro azido methyl tetrazole impurity in Losartan potassium. Based on detailed synthetic landscape, it is found t... [更多 ]
- |
- 2022
- |
- 2022-11-04
Tech Sheet on Dutasteride
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the prostate gland's initial development and subsequent enlargement. Testosterone is converted to DHT by the enzyme 5-alpha-reductase, which exists as 2- isoforms, type 1 a... [更多 ]
- |
- 2022
- |
- 2022-10-14
Tech Sheet on Linagliptin
Linagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of ... [更多 ]
- |
- 2022
- |
- 2022-10-12
Tech Sheet on Voriconazole
Voriconazole (Vfend®) is an azole antifungal indicated for invasive aspergillosis candidemia (non- neutropenic) and disseminated candidiasis in skin, abdomen, kidney, bladder wall, and wounds, and esophageal candidiasis. Furthermore, it is used to treat serious infections caused by scedosporium apio... [更多 ]
- |
- 2022
- |
- 2022-08-03
Co-Crystal and Customized Particle Size for Early Launch Opportunity of Siponimod API
Siponimod is an oral, second-generation sphingosine-1-phosphate (S1P) receptor modulator. S1P receptor modulators can inhibit the egress and recirculation of lymphocytes from lymph nodes, a therapeutic strategy for treating certain autoimmune diseases.Siponimod is the first and only treatment for pa... [更多 ]
- |
- 2022
- |
- 2022-07-29
New Product Alert – Lumateperone Tosylate API
Lumateperone is a serotonin 5HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM), and a serotonin transporter (SERT) inhibitor. Unlike existing schizophrenia treatments, Lumateperone is a first-in-class molecule that provides selective and simultaneous modulation of seroton... [更多 ]
- |
- 2022
- |
- 2022-06-15
Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings
Bempedoic acid (Brand: Nexletol, Innovator: Esperion) is an essentially new, oral treatment option approved for patients needing further LDL-C lowering beyond maximally tolerated statin therapy. Bempedoic acid is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for ... [更多 ]
- |
- 2022
- |
- 2022-04-04
Tech sheet: Dr. Reddy's Olaparib API Offerings
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostases, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib is indicated:As monotherapy in patients with deleterious or... [更多 ]
- |
- 2022
- |
- 2022-03-30
Tech sheet: Dr. Reddy's Enzalutamide API Offerings
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signalling pathway. Enzalutamide has been shown to inhibit androgen binding to androgen receptors competitively and consequently inhibits nuclear translocation of androgen receptors and their interac... [更多 ]
- |
- 2022
- |
- 2022-02-22
Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings
Eribulin Mesylate (Halaven®) is a microtubule inhibitor indicated to treat patients with:Metastatic breast cancer who have previously received at least two chemotherapeutic regimens to treat metastatic disease.Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing ... [更多 ]
- |
- 2022
- |
- 2022-02-09
Tech Sheet – Dr. Reddy’s Fexofenadine API offerings
Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. Fexofenadine Hydrochloride is indicated for:The relief of symptoms associated with seasonal allergic rhinitis in patients ≥ 2 years of age.To treat u... [更多 ]
- |
- 2022
- |
- 2022-02-04
Tech Sheet - Dr. Reddy’s Azacitidine API offerings
Azacitidine is a nucleoside metabolic inhibitor indicated to continue treating adult patients with acute myeloid leukemia. In addition, it is indicated for use in adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count r... [更多 ]
- |
- 2022
- |
- 2022-02-04
Tech Sheet - Dr. Reddy’s Ramipril API offerings
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor indicated for treating hypertension to lower blood pressure. ACE inhibitors inhibit the angiotensin-converting enzyme (ACE) actions, thereby reducing the production of angiotensin II and decreasing the breakdown of bradykinin. The decrease... [更多 ]
Year 2021
- |
- 2021
- |
- 2021-12-17
Tech Sheet - Dr. Reddy’s Gemcitabine API offerings
Gemcitabine Hydrochloride is an analog of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di-and triphosphate (dFdCDP and dFdCTP)dFdCDP - Inhibits ribonucleotide reductase, decreasing t... [更多 ]
- |
- 2021
- |
- 2021-12-02
Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 selectively and irreversibly via a covalent binding mechanism. Abiraterone is a CYP17 inhibitor indicated in combination with prednisolone to treat patients with metasta... [更多 ]
- |
- 2021
- |
- 2021-10-08
瑞德西韦（Remdesivir）系由瑞迪博士（Dr.Reddy’s）在吉利德（Gilead）许可下研发：
瑞德西韦是美国食品和药物管理局（FDA）批准的首种治疗新冠病毒病（COVID-19）的药物，用于需要住院治疗的成人和儿童患者（12岁或以上，体重至少40公斤）。它是新冠病毒RNA依赖的RNA聚合酶（RdRp）的抑制剂，对病毒的复制至关重要。除了美国食品和药物管理局，瑞德西韦已被多个监管机构授权紧急使用于治疗新冠病毒病，包括EMA（欧洲药品管理局）、MHLW（日本厚生劳动省）、PMDA（日本独立行政法人医药品及医疗器械综合管理机构药品和医疗设备机构）和CDSCO（印度中央药品标准控制组织）。要了解更多关于我们的产品，请填写联系表，阅读关于瑞德西韦 的白皮书... [更多 ]
- |
- 2021
- |
- 2021-08-17
白皮书： 瑞迪博士的2 DG - 一种对住院的新冠病毒病患者来极具前景的治疗方法
2-脱氧- D -葡萄糖（2-DG）是印度国防研究与发展组织（DRDO）核医学与有关科学研究所（INMAS）开发的一种抗病毒和抗炎药物。瑞迪博士与印度国防研究与发展组织合作，对新冠病毒病患者进行了2-DG的临床试验。基于印度的II期和III期研究，2-DG已获得紧急使用授权，可用作医院中度至重度新冠病毒病患者的辅助治疗。瑞迪博士是首家成功为新冠病毒病患者提供2-DG的公司。因此，我们能够让客户提早获得针对特定市场的原料药（API）和成品处方。想知道更多？please fill in the contact details to read the whitepaper on our 2 DG A... [更多 ]
- |
- 2021
- |
- 2021-08-17
技术表： 瑞迪博士的乐伐替尼（Lenvatinib）原料药产品
乐伐替尼是一种口服酪氨酸激酶抑制剂，可用于多种适应症，包括分化型甲状腺癌、肾细胞癌、肝细胞癌和子宫内膜癌。我们提供两种多晶型：1)甲磺酸乐伐替尼甲基异丁酮溶剂2)甲磺酸乐伐替尼C型。甲基异丁酮溶剂是一种新晶型，在多个市场上提供了比多晶型专利更早推出的优势。美国食品和药物管理局已经为以下两种晶型提交了申请：* 甲磺酸乐伐替尼甲基异丁酮溶剂，2018年6月。* 无水甲磺酸乐伐替尼C型，2021年6月。我们有能力满足全球对乐伐替尼原料药, 的需求，并能够在有需要时扩大规模以满足商业需求。 想了解更多有关我们原料药产品的信息，请填写下面的联系方式。... [更多 ]
- |
- 2021
- |
- 2021-06-18
罗沙司他（ROXADUSTAT）- 多管齐下的发展战略
在本白皮书中，我们概述了罗沙司他的各种发展战略如何在2020年3月成功填补美国药物主文件（USDMF），以助我们的跨地区合作伙伴为患者提供早期治疗。罗沙司他属首创新药，是小分子口服缺氧诱导因子脯氨酸羟化酶抑制剂（HIF-PHI），可增加内源性促红细胞生成素的产生，从而刺激血红蛋白和红细胞的产生。这种创新的方法在治疗慢性肾脏疾病（CKD）贫血患者方面取得了突破。我们可以通过粒径减小和结晶技术来满足定制的粒径分布要求，以在商业规模上始终如一地满足最理想的粒径分布。想了解更多关于我们产品的信息，请填写下面的联系表，阅读罗沙司他 阅读罗沙司他的技术表。... [更多 ]
- |
- 2021
- |
- 2021-05-19
瑞迪博士的阿普斯特片（Apremilast）原料药和成品配方产品。
Dr. Reddy's is one of the leading API pharma companies supplying Apremilast API globally, and has led the USDMF filing in September (Form-B) and June 2017 (Amorphous).阿普斯特片是一种抗炎药，在银屑病和银屑病关节炎中调节广泛的炎症介质。阿普斯特片适用于活动性银屑病关节炎和中度至重度斑块型银屑病。瑞迪博士的无定形原料药（API）已通过成功的生物等效性研究和随后的档案归档，成功地由多个配方商配制成药品。想了解更多关于我们产品的信息，请... [更多 ]
- |
- 2021
- |
- 2021-05-03
瑞迪博士的福沙吡坦（Fosaprepitant）原料药产品
福沙吡坦用于预防中度或高度致吐性化疗以及其他止吐药物引起的急性和迟发性恶心和呕吐。美国食品及药物管理局和欧洲药品管理局于2008年批准福沙吡坦，而日本独立行政法人医药品及医疗器械综合管理机构药品和医疗设备机构于2011年批准福沙吡坦。截至2020年12月，这相当于原料药每年500公斤的需求量（IQVIA MAT）。我们提供稳定的非晶型原料药，能够满足全球法规的要求和客户的配方需求。To know more about Dr. Reddy’s Fosaprepitant offerings Read the technical sheet on this topic by filling the... [更多 ]
- |
- 2021
- |
- 2021-04-15
阿哌沙班（Apixaban）原料药 - 易压缩颗粒和成品剂型
瑞迪博士是全球最早的阿哌沙班原料药仿制药生产商之一，并于2015年9月进行了美国药物主文件备案。我们的客户可以获得定制粒径的高质量原料药，以促进配方开发。阿哌沙班是一种抗凝血药物，于2011年在欧洲以艾乐妥（Eliquis）为商号获得批准，并于2012年在美国获得批准。 它最初经批准用于降低非瓣膜性心房颤动患者中风和全身性栓塞的风险。填写下面的联系表，阅读相关技术表。 探索其他白皮书：了解更多... [更多 ]
- |
- 2021
- |
- 2021-04-06
阿帕鲁胺（Apalutamide）原料药 - 对仿制药公司极具吸引力的NCE-1机遇
根据全球癌症统计报告2020年版（Globocan 2020）发布的估算，前列腺癌占了全球所有癌症病例的7.3%。 据估计，前列腺癌在世界范围内的5年患病率约为500万，使其成为男性中第二常见的癌症。阿帕鲁胺是一种口服二代非甾体雄激素受体抑制剂，并成为美国食品及药物管理局批准的首个用于非转移性去势抵抗性前列腺癌患者的药物。该药物于2019年获得额外批准，用于治疗转移性激素敏感性前列腺癌，目前正处于转移性激素难治性前列腺癌的3期临床试验。我们的API原料药允许配方商选择符合知识产权的市场准入，并满足监管要求。 我们提供的产品主要包括： 如果想继续阅读我们的白皮书，请填写下面的联系表 ... [更多 ]
- |
- 2021
- |
- 2021-04-06
胶体铁络合物（Colloidal Iron Complex）配方 - 认识和发展流程
本白皮书描述了发展 铁碳水化合物 复合体所涉及的挑战, 包括证明物理化学等效性所需的参数，并总结了我们在解决这些问题方面的专业知识。 铁碳水化合物是无机和有机分子的混合物。 分子的关键结构元素是由确定的流程单元操作和流程中使用的材料进行构建/支配的。 流程单元操作中的任何细微变化都能改变铁碳水化合物的结构特征想继续阅读，请填写以下联系表... [更多 ]
- |
- 2021
- |
- 2021-02-09
瑞迪博士的利伐沙班（Rivaroxaban）： 完整的原料药和成品配方产品
雷迪博士是最早的仿制药之一 原料药制造商 全球为 利伐沙班 API 并于 2014 年 3 月提交了 USDMF。 雷迪博士的 过程涉及选择性和有效的化学转化，为质量和可制造性提供独特的优势。该过程消除了过程中形成的潜在杂质，并且可以在商业规模上稳健且安全地运行。在选定的市场，我们还可以提供利伐沙班的制剂产品，并将在从申请到注册的所有监管方面为您提供支持。要了解有关我们的利伐沙班产品的更多信息，请填写下面的联系表，阅读技术表。 ... [更多 ]
- |
- 2021
- |
- 2021-01-22
瑞迪博士提供的阿尔法型和非晶型（Mirabegron） 原料药
通读我们的技术表 米拉贝隆 API了解我们的多步可扩展合成方法以及有效的分析表征，从而获得高纯度的 API。 Dr. Reddy's 是最早的仿制药之一 全球 API 制造商 并为 Mirabegron API 提交了 USDMF(α-form) 于 2014 年 6 月。我们还开发了 Mirabegron 的无定形形式，已于 2015 年 2 月在美国提交申请。通过填写下面的联系表阅读有关此主题的技术表。... [更多 ]
- |
- 2021
- |
- 2021-01-13
帕博西尼（Palbociclib） - 新流程开发方法如何提供知识产权优势
本白皮书概述了 Reddy 博士的整体开发方法如何帮助我们跨地区的 API 合作伙伴为患者提供早期使用的通用替代方案 帕博西尼 同时获得或保持竞争优势。我们的工艺专家团队利用他们对知识产权、工艺开发（API 和配方）的综合理解，以及 原料药制造 确保通过设计该过程是精益的，没有潜在的遗传毒性杂质和 可扩展以制造早期市场进入。要继续阅读我们最新的白皮书，请填写以下联系表格：您还可以通过单击下面的链接 探索我们的 Palbocicilb API 产品https://api.drreddys.com/zh-hans/product/palbociclib... [更多 ]
Year 2020
- |
- 2020
- |
- 2020-11-25
瑞迪博士的恶拉戈利（Elagolix ）原料药提供了全面的质量源于设计方法
我们的技术产品表 Elagolix API 描述了 质量源于设计 (QbD) Dr. Reddy's R& 采用的方法amp;D 团队开发产品。因此，Dr. Reddy's 是第一个也是少数几个通用 API 世界上的制造商在早期和商业规模上成功地验证了 Elagolix API 工艺。通过填写下面的联系表阅读有关此主题的技术表。您还可以通过单击以下链接探索我们的 Elagolix 产品：https://api.drreddys.com/zh-hans/product/elagolix-sodium... [更多 ]
- |
- 2020
- |
- 2020-07-20
沙库必曲/缬沙坦（Sacubitril/Valsartan）（LCZ696） - 通过创新的原料药产品带来另一个优势
我们的过程和分析专家团队利用他们对开发和分析的综合理解API的制造 和配方。当涉及到对成功的关键分子复合物的表征时，这一点尤为重要 API 和配方开发。这种整体观点也有助于更好地了解配方过程对产品分子完整性和稳定性的影响。因此，我们开发的这种超分子复合物能够与参考上市药物 (RLD) 的特征相匹配。填写下面的联系表格，阅读我们关于此主题的最新白皮书。您还可以探索我们的 Sacubitril/Valsartan (LCZ696) 产品 通过点击链接 以下：https://api.drreddys.com/zh-hans/product/sacubitril-valsartan... [更多 ]
- |
- 2020
- |
- 2020-07-10
瑞迪博士流动化学专家在《今日化学》（Chemistry Today）小组讨论会上分享了他们的观点
2020 年 6 月Reddy 博士的流动化学专家 Srividya Ramakrishnan 和 Rakeshwar Bandichhor 最近参加了“今日化学”的小组讨论，他们在会上分享了他们对流动技术及其成为复杂合成的卓越制造替代品的潜力的看法 活性药物成分 (API).请填写下面的联系我们表格以阅读有关此主题的文章。完整的出版物可在以下链接中找到：https://www.teknoscienze.com/tks_article/panel-discussion-on-flow-chemistry-3/... [更多 ]
- |
- 2020
- |
- 2020-05-20
进一步了解瑞迪博士如何满足雷诺嗪（Ranolazine）中基因毒性杂质的严格监管要求
基因毒性杂质 (GTI) 最近对制药业提出了挑战，因为它们在药品中的含量达到百万分之几 (ppm)，尤其是在高剂量分子中，如 雷诺嗪，其规定的最大每日剂量 (MDD) 为 2000 毫克。在本白皮书中，我们讨论了由 雷迪博士的 在产品开发阶段应对这一挑战 通过以这样一种方式设计工艺，使所有这些 PGI / GTI 都在制造方法的控制范围内，然后是 Reddy 博士的雷诺嗪。填写下面的联系表格，阅读我们关于此主题的最新白皮书。您还可以通过单击链接探索我们的雷诺嗪 API 产品 以下：https://api.drreddys.com/zh-hans/product/ranola... [更多 ]
- |
- 2020
- |
- 2020-05-07
法莫替丁（Famotidine）和尼扎替丁（Nizatidine）原料药： 受控的亚硝基二甲胺（NDMA），定制的颗粒分布，安全的供应链
20多年来，瑞迪博士一直是H2受体拮抗剂原料药（如法莫替丁和尼扎替丁）的最大制造商之一。 欧洲、美国、日本、中东和亚太地区的配方公司都在使用我们的替丁（Tidine）原料药。这些 API 根据亚硝胺杂质的国际指南制造和控制，可提供定制的粒度分布，以理想地满足您的配方需求。阅读技术表法莫替丁 and 尼扎替丁 通过填写下面的联系表格。您还可以通过单击以下链接探索我们的 Tidine API 产品：法莫替丁： https://api.drreddys.com/product/famotidine尼扎替丁： https://api.drreddys.com/produc... [更多 ]
Year 2019
- |
- 2019
- |
- 2019-10-17
满足沙坦（Sartan）原料药生产的新法规要求
原料药制造商 现在被要求审查其生产流程，并证明不含亚硝胺杂质。这份白皮书概述了相关法规和瑞迪博士的 Sartan 沙坦原料药（如缬沙坦（Valsartan））如何满足未来需求的案例研究。您可以通过点击以下链接查看我们的沙坦系列产品：:缬沙坦 - https://api.drreddys.com/product/valsartan洛沙坦 - https://api.drreddys.com/product/losartan-potassium替米沙坦厄贝沙坦... [更多 ]
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。